SJS Investment Consulting’s Ocular Therapeutix OCUL Stock Holding History

SJS Investment Consulting’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.92K	Buy	399 +232	+139%	+$2.1K	﹤0.01%	1482
2026 Q1	$1.42K	Buy	167 +2	+1%	+$19	﹤0.01%	1355
2025 Q4	$2K	Hold	165	–	–	﹤0.01%	1147
2025 Q3	$1.93K	Hold	165	–	–	﹤0.01%	833
2025 Q2	$1.53K	Hold	165	–	–	﹤0.01%	659
2025 Q1	$1.21K	Hold	165	–	–	﹤0.01%	939
2024 Q4	$1.41K	Hold	165	–	–	﹤0.01%	872
2024 Q3	$1.44K	Hold	165	–	–	﹤0.01%	939
2024 Q2	$1.13K	Hold	165	–	–	﹤0.01%	979
2024 Q1	$1.5K	Buy	+165	New	+$1.17K	﹤0.01%	879

Other funds holding OCUL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

SJS Investment Consulting's OCUL Position: Q2 2026 in Review

SJS Investment Consulting increased its Ocular Therapeutix (OCUL) stake by 139% in Q2 2026, buying an estimated $2.1K and bringing the position to 399 shares worth $3.92K. The position accounts for ﹤0.01% of the portfolio, ranked #1482.

SJS Investment Consulting first reported a position in OCUL in Q1 2024 and has held it in 10 quarters since. 92 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

SJS Investment Consulting held 399 shares of Ocular Therapeutix worth $3.92K as of Q2 2026.
SJS Investment Consulting bought 232 Ocular Therapeutix shares in Q2 2026, an estimated $2.1K.
Ocular Therapeutix made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1482 holding.
SJS Investment Consulting first reported a position in Ocular Therapeutix in Q1 2024 and has held it in 10 quarters since.
92 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.